Actively Recruiting
Phase 1 Study of JMT601 for Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma Evaluating Safety and Dose Levels
Led by Shanghai JMT-Bio Inc. · Updated on 2024-12-10
186
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating JMT601 in a Phase 1, open-label, multi-center study for adults with relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma who have received at least two prior therapies. The study aims to assess the safety of JMT601 and establish the recommended dose for future studies, addressing an important need for this type of lymphoma treatment. Participants receive JMT601 as an intravenous infusion once a week. The study has two parts a dose-escalation phase with up to six increasing dose levels to find the maximum tolerated dose and a dose-expansion phase using the recommended dose to further evaluate the treatment in two patient groups with different lymphoma types. The first four weeks include close monitoring for dose-limiting toxicities. During the study, participants undergo safety assessments including monitoring for dose-limiting toxicities and treatment-emergent adverse events up to 90 days after the last dose. Researchers will also evaluate effectiveness measures such as overall response rate, duration of response, progression-free survival, and overall survival for up to 12 months. Laboratory tests and drug concentration measurements are collected to understand drug behavior. The study continues until December 2025, with careful follow-up throughout.
CONDITIONS
Brief Title
A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
Research Team
Q
Qingjie Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here